Nine Chapters Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Nine Chapters Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,500	Closed	-$108K	–	314
2016 Q4	$108K	Buy	+10,500	New	+$96K	0.18%	145
2015 Q4	–	Sell	-38,000	Closed	-$713K	–	638
2015 Q3	$713K	Buy	+38,000	New	+$646K	0.06%	451

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nine Chapters Capital Management's CNCE Position: Q1 2017 in Review

Nine Chapters Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2017, closing a stake of 10,500 shares — an estimated $108K sold.

Nine Chapters Capital Management first reported a position in CNCE in Q3 2015 and held it in 2 quarters. The position peaked at $713K in Q3 2015. 85 funds tracked by Wall St. Rank hold CNCE as of Q1 2017.

Nine Chapters Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Nine Chapters Capital Management sold 10,500 Concert Pharmaceuticals, Inc. shares in Q1 2017, an estimated $108K.
Nine Chapters Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
Nine Chapters Capital Management's Concert Pharmaceuticals, Inc. position peaked at $713K in Q3 2015.
85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2017.

Based on Nine Chapters Capital Management's 13F filing for Q1 2017, filed 8 May 2017.